Cart
sales@molnova.com
Linzagolix
CAS No. 935283-04-8
Linzagolix( —— )
Catalog No. M27897 CAS No. 935283-04-8
Linzagolix is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which is under development by Kissei Pharmaceutical and ObsEva for the treatment of uterine fibroids, endometriosis, and adenomyosis.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 89 | In Stock |
|
| 5MG | 80 | In Stock |
|
| 10MG | 123 | In Stock |
|
| 25MG | 269 | In Stock |
|
| 50MG | 431 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLinzagolix
-
NoteResearch use only, not for human use.
-
Brief DescriptionLinzagolix is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which is under development by Kissei Pharmaceutical and ObsEva for the treatment of uterine fibroids, endometriosis, and adenomyosis.
-
DescriptionLinzagolix is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which is under development by Kissei Pharmaceutical and ObsEva for the treatment of uterine fibroids, endometriosis, and adenomyosis. As of December 2020, it is under review for approval for uterine fibroids, is in phase III clinical trials for endometriosis, and is in phase II clinical studies for adenomyosis.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorAntibacterial
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number935283-04-8
-
Formula Weight508.42
-
Molecular FormulaC22H15F3N2O7S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (245.86 mM)
-
SMILESCOc1cc(F)c(cc1OCc1c(OC)ccc(F)c1F)-n1c(=O)[nH]c2csc(C(O)=O)c2c1=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Trujillo C, Goya P, Rozas I. Study of Meldrum's Acid Cyclization Reactions. J Phys Chem A. 2018 Mar 8;122(9):2535-2541.
molnova catalog
related products
-
Thalidomide-O-amido-...
Thalidomide-O-amido-PEG4-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate incorporating the Thalidomide-based cereblon ligand and a linker.
-
Ethylmalonic acid
Ethylmalonic acid can be found in blood cerebrospinal fluid (CSF) and urine as well as in human fibroblasts prostate and skeletal muscle tissues. Moreover ethylmalonic acid is found to be associated with anorexia nervosa and malonyl-CoA decarboxylase deficiency. Ethylmalonic acid is a non-carcinogenic potentially toxic compound.
-
LX-4211 intermediate
LX-4211 intermediate a chemical compound.
